Bausch Health Companies Inc.(BHC) Stock Research - Grey Stern Research
Loading...

Bausch Health Companies Inc. (BHC) Stock Analysis

$6.81 (-2.71%)

BHC Financial Performance


Use the table below to view Bausch Health Companies Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $7.00 -
52 Week Low $3.96 -
52 Week High $11.46 -
Market Cap $2.6 Billion 7/10
Gross Margin 72% 2/10
Profit Margin 4% 5/10
EBITDA margin 33% 2/10
Q4 - 2024 Revenue $2.6 Billion 4/10
Q4 - 2024 Earnings $93.0 Million 4/10
Q4 - 2024 Free Cash Flow $494.0 Million 3/10
Trailing 4 Quarters Revenue $9.6 Billion 4/10
Trailing 4 Quarters Earnings -$45.7 Million 5/10
Quarterly Earnings Growth -76% 8/10
Annual Earnings Growth 94% 1/10
Quarterly Revenue Growth 6% 4/10
Annual Revenue Growth 5% 5/10
Cash On Hand $1.2 Billion 4/10
Short Term Debt $2.7 Billion 2/10
Long Term Debt $18.9 Billion 2/10

Bausch Health Companies Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Bausch Health Companies Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 5/10
PS 0.27 10/10
PB 0.00 10/10
PC 2.18 10/10
Liabilities to Equity 0.00 10/10
ROA 0.00 4/10
ROE 0.04 4/10
Current Ratio 0.99 10/10
Quick Ratio 0.04 9/10
Long Term Debt to Equity -14.81 10/10
Debt to Equity -16.90 10/10
Burn Rate 0.89 7/10
Cash to Cap 0.46 1/10
CCR 5.31 1/10
EV to EBITDA 26.98 8/10
EV to Revenue 2.39 5/10

Company Details

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

CEO: Mr. Joseph Papa

Website: https://www.bauschhealth.com

Address: 2150 Saint-Elzear Blvd W Laval, QUEBEC

Exchange: New York Stock Exchange

Industry: Drug Manufacturers—Specialty & Generic

Bausch Health Companies Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Bausch Health Companies Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Teva Pharmaceutical Industries Limited TEVA $18.0 Billion
Zoetis Inc. ZTS $72.9 Billion
PetIQ, Inc. PETQ $919.2 Million
Neurocrine Biosciences, Inc. NBIX $11.4 Billion
Catalent, Inc. CTLT $11.5 Billion
Emergent BioSolutions Inc. EBS $280.9 Million
Takeda Pharmaceutical Company Limited TAK $47.6 Billion
Tilray Brands, Inc. TLRY $614.4 Million
Viatris Inc. VTRS $10.7 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
BHC Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 2.6 Billion $93.0 Million
Q3 2024 $ 2.5 Billion -$85.0 Million
Q2 2024 $ 2.4 Billion $10.0 Million
Q1 2024 $ 2.1 Billion -$63.7 Million
Q4 2023 $ 2.4 Billion $395.0 Million
Q3 2023 $ 2.2 Billion -$378.0 Million
Q2 2023 $ 2.2 Billion $26.0 Million
Q1 2023 $ 1.9 Billion -$209.0 Million

View All

BHC Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $1.2 Billion $26.5 Billion $21.6 Billion -$322.0 Million
Q3 2024 $719.0 Million $26.5 Billion $21.5 Billion -$242.0 Million
Q2 2024 $622.9 Million $26.5 Billion $21.7 Billion -$227.0 Million
Q1 2024 $754.2 Million $26.9 Billion $22.1 Billion -$173.8 Million
Q4 2023 $947.0 Million $27.4 Billion $22.4 Billion -$82.0 Million
Q3 2023 $760.0 Million $27.1 Billion $22.4 Billion -$235.0 Million
Q2 2023 $767.3 Million $33.8 Billion $27.2 Billion -$878.6 Million
Q1 2023 $518.0 Million $25.4 Billion $20.7 Billion -$800.0 Million

View All

BHC Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 $494.0 Million -$107.0 Million $451.0 Million
Q3 2024 $341.8 Million -$69.3 Million $127.1 Million
Q2 2024 $299.7 Million -$79.0 Million -$131.3 Million
Q1 2024 $123.4 Million -$82.6 Million -$202.9 Million
Q4 2023 $248.9 Million -$78.3 Million $182.0 Million
Q3 2023 $236.0 Million -$46.0 Million $192.0 Million
Q2 2023 C$229.1 Million -C$39.7 Million C$61.0 Million
Q1 2023 $103.0 Million -$51.0 Million -$60.0 Million

View All